Abbott Laboratories (NYSE:ABT – Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, January 22nd. Analysts expect Abbott Laboratories to post earnings of $1.34 per share and revenue of $11,029,400.00 billion for the quarter. Persons that are interested in registering for the company’s earnings conference call can do so using this link.
Abbott Laboratories Stock Performance
Shares of ABT stock opened at $113.45 on Tuesday. The company has a market capitalization of $196.78 billion, a P/E ratio of 34.48, a P/E/G ratio of 2.40 and a beta of 0.73. Abbott Laboratories has a 12-month low of $99.71 and a 12-month high of $121.64. The business’s 50 day moving average is $114.93 and its two-hundred day moving average is $112.87. The company has a current ratio of 1.60, a quick ratio of 1.14 and a debt-to-equity ratio of 0.32.
Abbott Laboratories Increases Dividend
The business also recently declared a quarterly dividend, which will be paid on Friday, February 14th. Investors of record on Wednesday, January 15th will be paid a $0.59 dividend. The ex-dividend date of this dividend is Wednesday, January 15th. This represents a $2.36 dividend on an annualized basis and a yield of 2.08%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.55. Abbott Laboratories’s dividend payout ratio (DPR) is currently 66.87%.
Wall Street Analysts Forecast Growth
Check Out Our Latest Report on Abbott Laboratories
Abbott Laboratories Company Profile
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.
Read More
- Five stocks we like better than Abbott Laboratories
- Stock Dividend Cuts Happen Are You Ready?
- 3 Stocks to Gain From Donald Trump’s External Revenue Service
- What is Forex and How Does it Work?
- AMD: Loop Capital’s Buy Rating Reinforces Investor Confidence
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- Momentum Is Building for Qualcomm to Have a Strong Run in 2025
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.